Core Viewpoint - Medtronic's recent earnings report shows positive growth in earnings and revenues, but the stock has underperformed the S&P 500, raising questions about future performance leading up to the next earnings release [1][2]. Financial Performance - Medtronic reported Q2 fiscal 2026 adjusted earnings per share of $1.36, a 7.9% increase from the previous year, exceeding the Zacks Consensus Estimate by 3.82% [3]. - Total worldwide revenues for the quarter reached $8.96 billion, reflecting a 6.6% year-over-year increase and surpassing the Zacks Consensus Estimate by 1.11% [4]. Segmental Analysis - Cardiovascular segment revenues grew 9.3% organically to $3.44 billion, with Cardiac Rhythm & Heart Failure sales increasing 14.3% to $1.83 billion [5]. - Medical Surgical revenues totaled $2.17 billion, up 1.3% year over year, while Neuroscience revenues reached $2.56 billion, a 3.9% increase [6][7]. - Diabetes segment revenues rose 7.1% organically to $757 million [7]. Margin Performance - Gross margin expanded by 90 basis points to 65.8%, despite a 3.9% increase in the cost of products sold [8]. - Adjusted operating margin improved by 50 basis points year over year to 24.3% [8]. Fiscal Outlook - For fiscal 2026, Medtronic projects organic revenue growth of 5.5%, up from a previous estimate of approximately 5% [9]. - Full-year adjusted earnings per share are expected to be in the range of $5.62-$5.66, slightly revised from $5.60-$5.66 [10]. Estimate Trends - There has been a downward trend in estimates revisions over the past month, indicating a potential shift in investor sentiment [11][13]. VGM Scores - Medtronic currently holds a poor Growth Score of F, a Momentum Score of C, and a Value Score of B, resulting in an aggregate VGM Score of D [12].

Financial Data and Key Metrics Changes - The core business is expected to grow between 4%-7%, which aligns with the weighted average market growth rate of 4%-6% [6][8] - The company anticipates a short-term headwind due to three specific products not achieving the expected market adoption rate in 2026, impacting overall performance [7][15] - The stock is considered undervalued, with the fundamentals and core business remaining strong despite the current challenges [23][51] Business Line Data and Key Metrics Changes - The company focuses on fast-growing markets such as electrophysiology, neurovascular, structural heart, and neuromodulation, with 80% of the product development sales pipeline concentrated in these areas [4][5] - The electrophysiology portfolio has performed well over the past four to five years, although two specific products are facing adoption challenges [25][15] - The overall portfolio, excluding the impacted products, is still expected to grow at a strong double-digit rate [28] Market Data and Key Metrics Changes - The medical device market is experiencing significant innovation, particularly in electrophysiology and structural heart segments, which are expected to drive future growth [25][29] - The company has a global manufacturing footprint, which allows it to remain competitive despite potential tariff impacts [50][51] Company Strategy and Development Direction - The company aims to be the most innovative Contract Development and Manufacturing Organization (CDMO) in the world, focusing on building critical engineering and manufacturing capabilities [10][11] - The strategy includes targeted acquisitions to enhance capabilities and a strong emphasis on organic growth through innovative product launches [4][55] - The company is committed to maintaining operational efficiency through its Integer Production System, which focuses on lean manufacturing practices [39][40] Management's Comments on Operating Environment and Future Outlook - Management views the current challenges as a short-term air pocket, expecting to return to growth in the second half of 2026 and above-market growth in 2027 [8][61] - The company is confident in its strong pipeline and the ability to weather the current market pressures due to its diversified portfolio [17][63] - Management emphasizes the importance of customer relationships and market feedback in navigating product performance and demand [21][22] Other Important Information - A $200 million share repurchase program has been authorized, reflecting the board's confidence in the company's fundamentals and growth strategy [11][12] - The company has not previously engaged in share repurchase programs, indicating a strategic shift in capital allocation [12] Q&A Session Summary Question: What are the expectations for the company's growth in the coming years? - Management expects to return to market growth in the second half of 2026 and achieve above-market growth in 2027, driven by new product launches and a strong core business [60][61] Question: How does the company plan to manage costs during the current air pocket? - The company will focus on generating gross margin expansion through lean manufacturing and will be disciplined in managing fixed costs during this period [39][40] Question: What is the company's approach to acquisitions? - The company is focused on tuck-in acquisitions that enhance critical capabilities rather than transformative acquisitions, which were more common in the past [55]

Financial Data and Key Metrics Changes - The core business is expected to grow between 4% to 7% in 2026, which aligns with the weighted average market growth rate of 4% to 6% [6] - The company anticipates a short-term headwind due to three specific products that are not achieving the expected market adoption rates in 2026, impacting growth [6][7] - The stock is considered undervalued by management, reflecting strong fundamentals and financial strength [10][20] Business Line Data and Key Metrics Changes - The product development sales pipeline is approximately 80% focused on the fastest-growing markets, indicating a strong growth trajectory [5] - The electrophysiology portfolio has been performing well, with significant growth over the past four to five years, despite current headwinds [22][25] - The company is diversifying its portfolio, with no single program representing more than a few percentage points of total revenues, which mitigates risk [15] Market Data and Key Metrics Changes - The medical device market is experiencing a phase of multiple new product iterations, indicating a dynamic environment for innovation [21] - The company is well-positioned in the medtech ecosystem, partnering with both large and emerging companies [3] Company Strategy and Development Direction - The strategy focuses on building differentiated capabilities through organic growth and targeted acquisitions to enhance product offerings [4] - The company aims to be the most innovative contract development and manufacturing organization (CDMO) in the world, emphasizing engineering expertise and manufacturing efficiency [9][10] - Future growth is expected to be driven by new product launches in the second half of 2026 and into 2027, with a strong pipeline of innovative therapies [39][55] Management's Comments on Operating Environment and Future Outlook - Management views the current challenges as a short-term air pocket, expecting a return to growth in the second half of 2026 and above-market growth in 2027 [8][20] - The company is committed to maintaining operational efficiency and managing costs during this period, focusing on areas that will drive future growth [36] - Management is optimistic about the strength of the pipeline and the potential for market recovery, emphasizing the importance of execution and quality [9][20] Other Important Information - The company has initiated a $200 million share repurchase program, reflecting confidence in its financial strength and strategy [10] - The global manufacturing footprint is designed to mitigate risks associated with tariffs and ensure cost competitiveness [43][47] Q&A Session Summary Question: What is the outlook for the company's growth in 2026 and beyond? - Management expects to return to market growth in the second half of 2026 and achieve above-market growth in 2027, driven by new product launches and a strong pipeline [55][56] Question: How does the company manage costs during the current air pocket? - The company plans to focus on manufacturing efficiencies and be disciplined in managing fixed costs during this period [36] Question: What is the company's strategy regarding acquisitions? - The company is focused on tuck-in acquisitions to build critical capabilities rather than transformative acquisitions [49]

Financial Data and Key Metrics Changes - Sales for Q3 2025 totaled $468 million, reflecting an 8% growth on a reported basis and 7% growth organically [13][9] - Adjusted operating income increased by 14% year-over-year, with adjusted EPS growing by 25% to $1.79 [15][9] - For the full year 2025, the company expects sales growth between 7% and 8%, with adjusted operating income growth between 12% and 14% [20][10] Business Line Data and Key Metrics Changes - Cardio and vascular sales increased by 15% in Q3 2025, driven by new product ramps and strong demand in neurovascular [15] - Cardiac rhythm management solutions sales increased by 18% year-over-year, but growth is expected to decelerate in Q4 2025 due to anticipated declines in new products [16][10] - Neuromodulation sales increased by 2% in Q3 2025, with expectations for low single-digit growth for the full year [17] Market Data and Key Metrics Changes - The company anticipates a 3% to 4% headwind to total sales in 2026 due to slower market adoption of three new products [11][25] - The portable medical exit is expected to contribute a 2% headwind to total sales in 2026 [11][25] - The overall market in which the company competes is growing at a steady mid-single digit rate [29] Company Strategy and Development Direction - The company remains confident in its long-term growth strategy, focusing on early design wins in high-growth markets [12][29] - A strong product development pipeline is expected to drive above-market growth in 2027 [28][29] - The company plans to continue its acquisition strategy while maintaining a leverage ratio within the targeted range of 2.5 to 3.5x [29] Management's Comments on Operating Environment and Future Outlook - Management acknowledged recent customer forecast changes impacting the financial outlook but expressed confidence in the long-term strategy [5][10] - The company expects a recovery to market growth in the second half of 2026 as new product headwinds moderate [11][12] - Management highlighted the unusual nature of simultaneous forecast changes from multiple customers as a significant factor affecting the outlook [59] Other Important Information - The adjusted effective tax rate for Q3 2025 was 16.3%, down from 17.2% in the prior year, with expectations for the full year to be within the range of 17%-18% [18] - The company generated $66 million of cash flow from operations in Q3 2025, with free cash flow remaining flat at $46 million [19] Q&A Session Summary Question: Can you elaborate on the organic growth of the rest of the portfolio? - Management indicated that without new product introductions, the rest of the portfolio is expected to grow at market rates, which is lower than the typical 6%-8% growth [32][33] Question: What are the expected headwinds in the cardio and vascular items? - The headwinds are related to two electrophysiology products with slower market adoption than anticipated, not due to loss of market share [34][36] Question: How confident is the company in returning to market growth by Q4 2026? - Management expressed confidence due to steady backlog and customer forecasts, despite the unusual simultaneous changes in multiple products [38][39] Question: What is the nature of the changes in the electrophysiology products? - The changes are due to customers adjusting their forecasts based on lower-than-expected market adoption rates [42][46] Question: Is the decline in neuromodulation similar to electrophysiology? - Yes, the decline is attributed to slower market adoption from emerging customers, although the overall book of business is still growing [52][57] Question: How does the company plan to manage costs in 2026? - The company will focus on operational efficiencies and disciplined cost management to navigate the expected headwinds [85][86]

Financial Data and Key Metrics Changes - Sales for Q3 2025 totaled $468 million, reflecting an 8% growth on a reported basis and 7% growth organically [18] - Adjusted operating income increased by 14% year-over-year, with adjusted earnings per share (EPS) growing by 25% to $1.79 [13][20] - For the full year 2025, the company expects reported sales to be in the range of $1.84 billion to $1.85 billion, reflecting growth of 7% to 8% [25] Business Line Data and Key Metrics Changes - Cardio and Vascular sales increased by 15% in Q3 2025, driven by new product ramps in electrophysiology and strong demand in neurovascular [21] - Cardiac Rhythm Management and Neuromodulation sales grew by 2% year-over-year in Q3 2025, with expectations for low single-digit growth for the full year [22] - Adjusted net income for Q3 2025 was $63 million, up 27% year-over-year, driven by operational improvements and lower interest expenses [23][24] Market Data and Key Metrics Changes - The company anticipates a 3% to 4% headwind to total company sales in 2026 due to slower market adoption of three new products [15][32] - The expected organic sales growth for 2026 is flat to up 4%, with reported sales expected to decline by 2% to increase by 2% [16][31] Company Strategy and Development Direction - The company remains confident in its long-term growth strategy, focusing on early design wins in high-growth markets [17][35] - A strong product development pipeline is expected to drive above-market organic sales growth in 2027 [34] - The company plans to continue its tuck-in acquisition strategy while maintaining a leverage ratio within the targeted range of 2.5 to 3.5 times [36] Management Comments on Operating Environment and Future Outlook - Management acknowledged recent customer forecast changes impacting the financial outlook but expressed confidence in the long-term strategy [6][8] - The company expects a recovery to market growth in the second half of 2026 as new product headwinds moderate [16][17] - Management emphasized that the recent forecast changes are unusual and not expected to recur [108] Other Important Information - The adjusted effective tax rate for 2025 is expected to be between 17% and 18%, an improvement from previous guidance [24] - The company generated $66 million in cash flow from operations in Q3 2025, with free cash flow remaining flat at $46 million [24] Q&A Session Summary Question: Can you elaborate on the organic growth expectations for the rest of the portfolio? - Management indicated that without new product introductions, the rest of the portfolio is expected to grow at market rates, which is typically 6% to 8% [40] Question: What are the expected headwinds for Cardio and Vascular products? - The headwinds are related to two electrophysiology products with slower-than-anticipated market adoption, impacting growth forecasts [45][46] Question: How confident is the company in returning to market growth in the second half of 2026? - Management expressed confidence due to steady backlog and customer forecasts, despite recent changes [47][49] Question: Were the changes in forecasts known prior to Q3? - Management confirmed that the changes were not known until Q3, which is unusual for multiple products to experience significant forecast changes simultaneously [53][108] Question: Is the decline in neuromodulation sales similar to that in electrophysiology? - Yes, the decline is attributed to slower market adoption among select customers, similar to the dynamics seen in electrophysiology [61][66] Question: How does the company plan to manage profitability in 2026? - The company plans to focus on cost management and operational efficiencies to maintain profitability despite expected sales challenges [98]